Stryker, Humana, and Gilead Sciences are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare, such as pharmaceutical and biotechnology firms, medical-device makers, and healthcare providers. Investors may buy them to gain exposure to healthcare demand and innovation, though their performance can be affected by factors such as regulation, clinical-trial results, and changes in healthcare spending. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Stryker (SYK)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
NYSE:SYK traded down $9.81 during trading hours on Friday, reaching $325.26. 3,778,566 shares of the company were exchanged, compared to its average volume of 2,751,012. Stryker has a 1-year low of $267.00 and a 1-year high of $389.33. The business has a 50 day moving average of $292.37 and a 200 day moving average of $323.59. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30. The company has a market capitalization of $123.83 billion, a P/E ratio of 34.64, a P/E/G ratio of 2.11 and a beta of 0.78.
Read Our Latest Research Report on SYK
Humana (HUM)
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
NYSE:HUM traded up $20.90 during trading hours on Friday, hitting $432.69. The company's stock had a trading volume of 2,576,136 shares, compared to its average volume of 1,620,345. The stock has a fifty day simple moving average of $403.96 and a 200-day simple moving average of $312.27. Humana has a twelve month low of $163.11 and a twelve month high of $456.50. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. The company has a market capitalization of $51.96 billion, a P/E ratio of 40.94, a PEG ratio of 2.53 and a beta of 0.65.
Read Our Latest Research Report on HUM
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of Gilead Sciences stock traded down $0.68 on Friday, hitting $166.89. The stock had a trading volume of 5,817,414 shares, compared to its average volume of 6,406,722. The firm has a market capitalization of $207.00 billion, a P/E ratio of -52.81 and a beta of 0.35. Gilead Sciences has a twelve month low of $116.88 and a twelve month high of $176.58. The stock has a 50 day moving average of $153.04 and a 200 day moving average of $140.94. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38.
Read Our Latest Research Report on GILD
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
